Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lademirsen in Alport syndrome
2019-004394-10Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alport syndrome comparing Lademirsen with Placebo (2 arms). Primary endpoint: Number of participants with treatment-emergent adverse events and serious adverse events. Started Dec 2019; status: completed.
02
Drugs
lademirsen
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on 2019-004394-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004394-10.